Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study
{{output}}
Background: The use of targeted therapies, such as BRAF/MEK inhibitors, has led to a considerable increase in melanoma-specific survival rates; however, prolonged responses remain uneven and uncertain. Moreover, there is a lack o... ...
